Sculptor Capital’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Sculptor Capital’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-767,528	Closed	-$7.67M	–	751
2022 Q4	$7.67M	Hold	767,528	–	–	0.13%	181
2022 Q3	$7.47M	Hold	767,528	–	–	0.09%	273
2022 Q2	$7.44M	Buy	767,528 +3,900	+0.5%	+$37.9K	0.08%	307
2022 Q1	$7.42M	Buy	763,628 +476,127	+166%	+$4.6M	0.06%	327
2021 Q4	$2.82M	Buy	287,501 +227,461	+379%	+$2.23M	0.02%	520
2021 Q3	$590K	Buy	+60,040	New	+$593K	﹤0.01%	631

Other funds holding DALS

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sculptor Capital's DALS Position: Q1 2023 in Review

Sculptor Capital sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q1 2023, closing a stake of 767,528 shares — an estimated $7.67M sold.

Sculptor Capital first reported a position in DALS in Q3 2021 and held it in 6 quarters. The position peaked at $7.67M in Q4 2022. 50 funds tracked by Wall St. Rank hold DALS as of Q1 2023.

Sculptor Capital reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Sculptor Capital sold 767,528 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q1 2023, an estimated $7.67M.
Sculptor Capital first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 6 quarters.
Sculptor Capital's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $7.67M in Q4 2022.
50 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q1 2023.

Based on Sculptor Capital's 13F filing for Q1 2023, filed 16 May 2023.